ClinicalTrials.gg
CompletedNCT04828343Updated Mar 7, 2024Results posted

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

A Phase 1 interventional study of rozanolixizumab and Placebo in Healthy Study Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.

02

Conditions studied

  • Healthy Study Participants

Keywords

  • Healthy Study Participants
  • Phase 1
  • rozanolixizumab
  • manual push
  • syringe driver
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 18 to 65 years of age, inclusive
  • Study participants who are overtly healthy in the opinion of the investigator as determined by medical evaluation including medical history, a general clinical examination, including physical examination and laboratory tests, and cardiac monitoring
  • Study participant has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes of rest (systolic BP: 90 to 140 mmHg, diastolic BP: 50 to 90 mmHg, pulse: 40 to 90 beats per minute (bpm))
  • Study participant has clinical laboratory test results within the reference ranges of the testing laboratory or not if outside the specified ranges, in the opinion of the investigator
  • Study participant's (ECG) is considered "normal" or "abnormal but clinically nonsignificant" (as interpreted by the investigator)
  • Study participants may be male or female
  • Participant has a of 18 to 32 kg/m\^2, with a minimum body weight of 35 kg

Exclusion criteria

Exclusion Criteria:

  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders. Has active neoplastic disease or history of neoplastic disease within the previous 5 years of entry in the clinical study (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care approaches). Has a history of a major organ transplant or hematopoietic stem cell/marrow transplant
  • Symptomatic herpes zoster within 3 months prior to Screening
  • Allergies to humanized monoclonal antibodies
  • Female who is pregnant or lactating
  • multiple or severe drug allergies, intolerance to topical , or severe posttreatment reactions
  • Evidence of active or latent tuberculosis (TB) as documented by medical history and examination
  • Predicted inability to comply with being free of caffeine and ethanol from 72 hours prior to clinic admission and during the In-Clinic Period of the study
  • Known hypersensitivity to oral paracetamol (acetaminophen)
  • History of known inflammatory bowel disease, active diverticular disease, or a history of confirmed duodenal, gastric, or esophageal ulceration in the previous 6 months
  • History of hyperprolinemia, since L-proline is a constituent of rozanolixizumab.
  • Twelve-lead with abnormalities considered to be clinically significant upon medical review
  • Renal impairment, defined as a creatinine concentration in serum of ≥1.4 mg/dL (≥123 μmol/L) for female participants and ≥1.5 mg/dL (≥132 μmol/L) for male participants
  • Known viral hepatitis (B and C) or 1/2 antibodies or has a past medical history or family history of primary immunodeficiency or antibodies to human immunodeficiency virus type 1 and/or type 2 at Screening
  • Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in reverse transcriptase-polymerase chain reaction on admission to the unit
  • Participant has clinical signs and symptoms consistent with SARS-CoV-2 (eg, fever, dry cough, dyspnea, sore throat, fatigue) or confirmed infection by appropriate laboratory test within the previous 14 days prior to Screening or on admission
  • Participant has active infection or is symptomatic with SARS-CoV-2 or is currently in quarantine (has been in contact with a SARS-CoV-2 positive individual in the last 14 days)
  • Participant has had a severe course of SARS-CoV-2 (eg, requiring extracorporeal membrane oxygenation, mechanical ventilation, or hospitalization)
  • Past or intended use of over-the-counter or prescription medication (including herbal medications) within 14 days prior to dosing until Day 57
  • (s) within 8 weeks prior to Screening or plans to receive such vaccines during the study or is within a dosing cycle to receive a second dose of a coronavirus disease-19 (COVID-19) vaccine, or within 2 weeks of having received a COVID-19 vaccine
  • Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
  • Exposure to more than 3 new chemical entities within 12 months prior to dosing
  • Has previously been assigned to treatment in a clinical study of rozanolixizumab
  • Participated in another study of an medicinal product (IMP) (or a medical device) within the previous 90 days or 5 half-lives prior to Day -1 (whichever is longer) or is currently participating in another study of an IMP (or a medical device)
  • Immunoglobulin G \<7g/L or >16g/L at the Screening Visit
  • Participant is splenectomized or has had an active clinically significant infection within the last 6 weeks
  • Donated or lost >500 mL of blood or blood products in the 3 months preceding the start of dosing or plans to donate blood during the clinical study
  • Employee or direct relative of an employee of the contract research organization (CRO) or UCB
  • History of alcohol and/or drug abuse up to 12 months before Screening
  • Smoked on average >5 cigarettes/day (or equivalent) during the last 3 months and is not able to stop smoking during the In-Clinic Period
  • Excessive consumption of beverages or food containing xanthine bases (including caffeinated drinks, coffee, chocolate, etc.), equating to >400 mg caffeine per day
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1 <50 kg

    Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.

    Drug: rozanolixizumab · Other: Placebo

  • Experimental
    Cohort 2 <50 kg

    Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.

    Drug: rozanolixizumab · Other: Placebo

  • Experimental
    Cohort 3 >=50 kg

    Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.

    Drug: rozanolixizumab · Other: Placebo

  • Experimental
    Cohort 4 >=50 kg

    Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.

    Drug: rozanolixizumab · Other: Placebo

Interventions

  • Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

    Also known as: RLZ

  • OtherPlacebo

    Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event (AE) with a start date/time on or after first dose of study medication until 8 weeks after dosing of study medication.

    Time frame: From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab

    Cmax was the maximum plasma concentration of a single dose rozanolixizumab. Cmax was measured in micrograms per millilitre per milligram (ug/mL/mg).

    Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16

  2. Time to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab

    tmax was the time to maximum plasma concentration of a single dose rozanolixizumab.

    Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab

    AUC0-t was the area under the plasma concentration-time curve from time zero to time t of a single dose rozanolixizumab.

    Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16

  4. Baseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve

    Area under the baseline-corrected total IgG response curve from time 0 to time t.

    Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57

  5. Percent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo

    Rmin was the maximum (max) decrease in total plasma IgG of a single dose rozanolixizumab or placebo.

    Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57

  6. Time to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo

    tmin was the time to minimum IgG level of a single dose rozanolixizumab or placebo.

    Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57

07

Results

Posted Mar 7, 2024

Participant flow

The study started to enroll participants in April 2021 and concluded in April 2022.

Participant flow — Overall Study
MilestoneCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
Started62626262
Completed62626262
Not completed00000000

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event (AE) with a start date/time on or after first dose of study medication until 8 weeks after dosing of study medication.

Time frame:
From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)83.350.010050.083.3083.3100
SecondaryMaximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab

Cmax was the maximum plasma concentration of a single dose rozanolixizumab. Cmax was measured in micrograms per millilitre per milligram (ug/mL/mg).

Time frame:
Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Reported as:
Geometric mean · ug/mL/mg
Maximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab
ug/mL/mgCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)
Maximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab0.03352 ± 52.80.004066 ± 127.00.007293 ± 644.10.02752 ± 82.2
SecondaryTime to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab

tmax was the time to maximum plasma concentration of a single dose rozanolixizumab.

Time frame:
Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab
hoursCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)
Time to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab60.10 (36.0 to 72.4)48.03 (36.0 to 72.1)72.00 (36.0 to 96.3)72.00 (36.0 to 96.1)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab

AUC0-t was the area under the plasma concentration-time curve from time zero to time t of a single dose rozanolixizumab.

Time frame:
Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Reported as:
Geometric mean · hours*ug/mL/mg
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab
hours*ug/mL/mgCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab2.408 ± 55.40.1436 ± 266.70.4223 ± 687.02.111 ± 80.5
SecondaryBaseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve

Area under the baseline-corrected total IgG response curve from time 0 to time t.

Time frame:
Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
Reported as:
Mean · grams*day/Litre (g*day/L)
Baseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve
grams*day/Litre (g*day/L)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
Baseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve-190.6 ± 66.10NA ± NA-101.0 ± 118.4NA ± NA-141.8 ± 52.99NA ± NA-168.8 ± 49.70NA ± NA
SecondaryPercent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo

Rmin was the maximum (max) decrease in total plasma IgG of a single dose rozanolixizumab or placebo.

Time frame:
Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
Reported as:
Mean · percent max decrease in total plasma IgG
Percent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo
percent max decrease in total plasma IgGCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
Percent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo-46.73 ± 14.76NA ± NA-42.14 ± 13.31NA ± NA-44.03 ± 8.711NA ± NA-42.90 ± 10.67NA ± NA
SecondaryTime to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo

tmin was the time to minimum IgG level of a single dose rozanolixizumab or placebo.

Time frame:
Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
Reported as:
Median · days
Time to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo
daysCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
Time to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo12.08 (8.98 to 42.0)NA (6.08 to 9.16)11.07 (6.11 to 15.1)NA (4.00 to 42.1)9.012 (5.97 to 12.1)NA (5.96 to 15.1)10.55 (4.00 to 15.0)NA (2.00 to 8.95)

Adverse events

Collected over From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)0/2 (0%)0/2 (0%)1/2 (50%)
Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)0/6 (0%)0/6 (0%)6/6 (100%)
Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)0/2 (0%)0/2 (0%)1/2 (50%)
Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 3: Syringe Driver- PBO (>=50 kg)0/2 (0%)0/2 (0%)0/2 (0%)
Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 4: Manual Push- PBO (>=50 kg)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventCohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)
HeadacheNervous system disorders4/60/23/60/22/60/22/61/2
Abdominal pain upperGastrointestinal disorders0/60/20/61/21/60/20/60/2
Gingival bleedingGastrointestinal disorders0/61/20/60/20/60/20/60/2
NauseaGastrointestinal disorders0/60/20/61/21/60/20/60/2
Infusion site erythemaGeneral disorders3/60/22/60/21/60/21/60/2
PyrexiaGeneral disorders2/60/20/61/23/60/20/60/2
Aspartate aminotransferase increasedInvestigations0/60/20/60/20/60/20/61/2
DiarrhoeaGastrointestinal disorders0/60/20/60/22/60/20/60/2
VomitingGastrointestinal disorders0/60/20/60/22/60/20/60/2
Infusion site painGeneral disorders2/60/21/60/20/60/20/60/2

Baseline characteristics

Baseline Characteristics refer to the Safety Analysis Set which consisted of all randomized study participants who received investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)Total
<=18 years000000000
Between 18 and 65 years6262626232
>=65 years000000000
Age, Continuous
Age, Continuous(years)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)Total
Mean36.7 ± 15.7NA ± NA33.2 ± 9.5NA ± NA39.3 ± 8.1NA ± NA45.5 ± 12.7NA ± NA37.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)Total
Female6262202121
Male0000424111
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)Total
Asian4162000013
Black or African American000000101
White2100424215
Other or Mixed000020103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg)Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg)Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg)Cohort 2: Manual Push- PBO (>=35 kg to <50 kg)Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg)Cohort 3: Syringe Driver- PBO (>=50 kg)Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg)Cohort 4: Manual Push- PBO (>=50 kg)Total
Hispanic or Latino100020104
Not Hispanic or Latino5262425228
08

Study locations

1 site
  • Up0106 001
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Apr 2022, 11 months.

Results were first posted in Mar 2024, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Apr 2, 2021
StartActual
Apr 22, 2021
Primary completionActual
Apr 11, 2022
CompletionActual
Apr 11, 2022
Results first posted
Mar 7, 2024
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04828343
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
Apr 22, 2021
Primary completion
Apr 11, 2022
Completion
Apr 11, 2022
Results posted
Mar 7, 2024
Last update
Mar 7, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion